London – Paul Hastings LLP, a leading global law firm, announced today that it is advising Masimo LHC Limited, a wholly-owned indirect subsidiary of Masimo Corporation (“Masimo”), on its recommended cash acquisition of the entire issued and to be issued share capital of LidCo Group plc (“LidCo”).
The acquisition was announced on 2 November 2020.
Masimo is a global medical technology company that develops, manufactures, distributes, and licenses innovative patient monitoring technologies, medical devices, and a wide array of sensors. LidCo is a market leader for the provision of advanced hemodynamic monitoring products in the UK and has a growing presence in the US and many other international markets.
The Paul Hastings team was led by London partner Matthew Poxon and senior associate David Prowse with support from corporate associates Catherine Kennedy and Rebecca Denton. The Paul Hastings team also included employment partner Suzanne Horne and associate Aashna Parekh and tax partner Jiten Tank and associate Hannah Gray. Masimo relationship partner Jeff Hartlin and associate Regina Mendoza advised on the US securities aspects of the transaction.
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.